Robert Hazlett
Stock Analyst at BTIG
(0.66)
# 3,806
Out of 4,761 analysts
25
Total ratings
34.38%
Success rate
-18.23%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $7.51 | +219.57% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $4 | $0.93 | +329.09% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $1.66 | +743.37% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $24 → $20 | $0.21 | +9,622.90% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $137.75 | -28.86% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $5.68 | +956.34% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $4.21 | +1,396.44% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $15.56 | +86.38% | 4 | Feb 2, 2021 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $80 → $40 | $128.60 | -68.90% | 2 | Nov 2, 2020 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $4.76 | +546,118.49% | 1 | Sep 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $6 | $1.80 | +233.33% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $27 | $10.03 | +169.19% | 2 | Oct 16, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $7.51
Upside: +219.57%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $4
Current: $0.93
Upside: +329.09%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $1.66
Upside: +743.37%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $24 → $20
Current: $0.21
Upside: +9,622.90%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $137.75
Upside: -28.86%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $5.68
Upside: +956.34%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $4.21
Upside: +1,396.44%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $15.56
Upside: +86.38%
Intra-Cellular Therapies
Nov 2, 2020
Maintains: Buy
Price Target: $80 → $40
Current: $128.60
Upside: -68.90%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $4.76
Upside: +546,118.49%
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $1.80
Upside: +233.33%
Oct 16, 2017
Maintains: Buy
Price Target: $18 → $27
Current: $10.03
Upside: +169.19%